

## Quarterly Activities Report for the Period Ended 30 September 2025

### Financial Updates

- Net cash outflow from operating activities of \$576k
- Quarterly receipts from customers were \$540k

**Sydney, Australia – 15 October 2025:** Cannabis focused distribution company, Bod Science Limited (Subject to a Deed of Company Arrangement) (“Bod” or “the Company”) (ASX: BOD), provides the following update on activities for the three-month period ended 30 September 2025 (Q1 FY2026).

### Operational Overview:

In April 2024, Bod entered into a Deed of Company Arrangement (“DOCA”) with Biortica Agrimed Limited (“Biortica”) in accordance with that DOCA proposal. Pursuant to the DOCA, Andrew Barnden has been appointed as Deed Administrator and the Company continues to trade under the DOCA. The Company will remain in suspension throughout the deed administration process.

In November 2024, the Company executed a binding conditional Share Purchase Agreement with the Biortica ordinary shareholders to acquire all the fully paid ordinary shares in Biortica, in consideration for the issue of ordinary shares in the Company.

The DOCA will be effectuated once the conditions subsequent to the DOCA are satisfied, in particular, the passing of the various resolutions by shareholders at an extraordinary general meeting of the Company. Due to a delay in respect to the completion of the audit of Biortica, the DOCA period has been further extended to 20 November 2025 after receipt of a further payment from Biortica to assist with the additional costs incurred. The extraordinary general meeting of the shareholders of the Company is expected to be convened on or before 30 October 2025, being a date after Biortica complies with the majority of the conditions subsequent, with the meeting to be held in late November 2025. The actual date of the extraordinary general meeting will be advised in a formal Notice of Meeting, which will be issued in due course.

### Financial Overview:

Net cash outflow from operating activities of \$576k decreased by \$1,434k on Q4 FY2025 (net inflow of \$858k). This decrease was driven by the payment of administration and other fees incurred since the start of the administration period of \$1,059k and the receipt during Q4 FY2025 of the FY24 R&D tax incentive of \$678k, partially offset by increased cash receipts from customers and increased funding income from Biortica. The Q1 FY2026 net cash outflow was \$572k higher than the previous corresponding period (“PCP”) (Q1 FY2025: \$4k) due to the payment of administration and other fees incurred since the start of the administration period of \$1,059k, partially offset by increased cash receipts from customers, increased funding from Biortica and reduced staff costs.

Quarterly receipts from customers were \$540k, an increase of \$152k (39%) on the last quarter (Q4 FY2025: \$388k) and an increase of \$348k (181%) on the PCP (Q1 FY2025: \$192k). The increase on the last quarter and the PCP is due to a combination of increases in sales volumes of existing SKUs and by the introduction of new SKUs.

Other receipts from operating activities of \$496k represents funding received from Biortica to partially pay for the Company’s operating expenses.

The Company made payments totalling \$35k to related parties during the quarter, representing remuneration paid to a director.

**Outlook:**

The second meeting of the Company's creditors was held on 8 April 2024. The outcome of the meeting was, inter alia, that the Company's creditors accepted the DOCA proposal and the DOCA was subsequently executed on 24 April 2024.

The Company has entered into a binding Share Purchase Agreement with the ordinary shareholders of Biortica. The Share Purchase Agreement is subject to conditions subsequent being met, together with the effectuation of the DOCA and the Company satisfying the re-compliance requirements with Chapter 1 and 2 of the ASX Listing Rules, including all necessary shareholder approvals.

It is expected that a notice of meeting will be sent to the Company's shareholders soon after Biortica comply with the conditions subsequent, informing them that an extraordinary general meeting has been scheduled at which the shareholders will vote upon whether to approve the various resolutions as detailed in Biortica's DOCA proposal.

**This announcement has been approved by the Deed Administrator of Bod Science Limited (Subject to a Deed of Company Arrangement).**

**-ENDS-**

**About Bod Science:**

Bod Science Limited (Subject to a Deed of Company Arrangement) (ASX:BOD) is a cannabis focused distribution company.

**For more information please contact:**

Andrew Barnden  
Deed Administrator  
abarnden@rogersreidy.com.au  
+61 2 9262 1944

For personal use only